These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15168808)

  • 41. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies: implications for diagnosis and follow-up of children with Crohn's disease.
    Canani RB; Romano MT; Greco L; Terrin G; Sferlazzas C; Barabino A; Fontana M; Roggero P; Guariso G; De Angelis G; Fecarotta S; Polito G; Cucchiara S
    Inflamm Bowel Dis; 2004 May; 10(3):234-9. PubMed ID: 15290917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
    Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
    Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.
    Sutton CL; Yang H; Li Z; Rotter JI; Targan SR; Braun J
    Gut; 2000 Jan; 46(1):58-63. PubMed ID: 10601056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.
    McKenzie H; Main J; Pennington CR; Parratt D
    Gut; 1990 May; 31(5):536-8. PubMed ID: 2190866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.
    Israeli E; Grotto I; Gilburd B; Balicer RD; Goldin E; Wiik A; Shoenfeld Y
    Gut; 2005 Sep; 54(9):1232-6. PubMed ID: 16099791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens.
    Müller S; Schaffer T; Flogerzi B; Seibold-Schmid B; Schnider J; Takahashi K; Darfeuille-Michaud A; Vazeille E; Schoepfer AM; Seibold F
    Gut; 2010 Nov; 59(11):1493-500. PubMed ID: 20682699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease.
    Bahari A; Aarabi M; Aarabi M; Hedayati M; Jarollahi A; Firouzi F; Aghazadeh R; Zali MR; Hashemi M
    Acta Gastroenterol Belg; 2009; 72(3):301-5. PubMed ID: 19902862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.
    Cruyssen BV; Peeters H; Hoffman IE; Laukens D; Coucke P; Marichal D; Cuvelier C; Remaut E; Veys EM; Mielants H; De Vos M; De Keyser F
    Clin Exp Immunol; 2005 May; 140(2):354-9. PubMed ID: 15807862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen?
    Seibold F
    Gut; 2005 Sep; 54(9):1212-3. PubMed ID: 16099786
    [No Abstract]   [Full Text] [Related]  

  • 50. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.
    Klebl FH; Bataille F; Bertea CR; Herfarth H; Hofstädter F; Schölmerich J; Rogler G
    Inflamm Bowel Dis; 2003 Sep; 9(5):302-7. PubMed ID: 14555913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.
    Giaffer MH; Clark A; Holdsworth CD
    Gut; 1992 Aug; 33(8):1071-5. PubMed ID: 1398231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
    Esters N; Vermeire S; Joossens S; Noman M; Louis E; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; Poulain D; Bossuyt X; Rutgeerts P;
    Am J Gastroenterol; 2002 Jun; 97(6):1458-62. PubMed ID: 12094865
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome.
    Alunno A; Bistoni O; Carubbi F; Valentini V; Cafaro G; Bartoloni E; Giacomelli R; Gerli R
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):73-79. PubMed ID: 28664835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Interest of serologic markers in inflammatory bowel disease. About 105 cases].
    Fekih M; Ben Hlima S; Zitouni M; Matri S; Boubaker J; Makni S; Azza F
    Tunis Med; 2007 Oct; 85(10):821-8. PubMed ID: 18236802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease].
    Barta Z; Csípö I; Antal-Szalmás P; Sipka S; Szabó G; Szegedi G
    Orv Hetil; 2001 Oct; 142(42):2303-7. PubMed ID: 11760647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease.
    Dassopoulos T; Frangakis C; Cruz-Correa M; Talor MV; Burek CL; Datta L; Nouvet F; Bayless TM; Brant SR
    Inflamm Bowel Dis; 2007 Feb; 13(2):143-51. PubMed ID: 17206688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparison of five techniques to detect anti-Saccharomyces cerevisiae antibodies (ASCA) in serum for diagnosing Crohn's disease].
    Le Goff C; Chapelle JP; Lutteri L
    Ann Biol Clin (Paris); 2007; 65(6):601-8. PubMed ID: 18039604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.
    Duman AE; Hülagü S; Çelebi A; Korkmaz U; Musul MM; Şentürk Ö; Şirin G; Yılmaz H; Koç DÖ; Dindar G; Öztürkler M; Bozkurt N; Kır HM
    Turk J Gastroenterol; 2019 Jan; 30(1):21-27. PubMed ID: 30465525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies are not increased in Takayasu arteritis.
    Ozbakir F; Ugurlu S; Celik AF; Seyahi E
    Acta Reumatol Port; 2011; 36(1):20-3. PubMed ID: 21483276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
    Mokrowiecka A; Gasiorowska A; Małecka-Panas E
    Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.